Search results for "Diabetes mellitus."

showing 10 items of 2067 documents

249 Validation of assessment of circulate oxidative stress markers by the Free Oxygen Radicals Testing (FORT) assay among patients with an acute myoc…

2011

BackgroundFree oxygen radicals play an important role in the pathogenesis of many diseases including cardiovascular diseases, diabetes, cancer and aging. Several methods were developed for the direct or indirect measurement of oxygen free radical and its by-products. Using a new Free Oxygen Radicals Testing (FORT) the current study is designed first to validate the device and to investigate the potential relationships between the ROS and clinical or biological factors in human serum from a population of men with an acute myocardial infarction (AMI).MethodsWe first determined the effect of storage, variability and reproducibility of the FORT test in serum. Then we used the test in 66 patient…

medicine.medical_specialtyUnivariate analysiseducation.field_of_studyEjection fractionbusiness.industryPopulationCancermedicine.disease_causemedicine.diseaseSurgeryPathogenesisDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinesseducationOxidative stressArchives of Cardiovascular Diseases Supplements
researchProduct

CT imaging of acute and chronic pyelonephritis: a practical guide for emergency radiologists

2020

Contrast-enhanced CT is not routinely indicated in uncomplicated urinary infections, but it may be necessary in patients with specific risk factors (i.e., diabetes, immunocompromised patients, history of stones, or prior renal surgery) or in patients not responding to antibiotics and in detecting complications of pyelonephritis. CT is the gold standard for imaging assessment of pyelonephritis severity. Imaging appearance of acute pyelonephritis, including focal (i.e., wedge-shaped zones of decreased attenuation or hypodense mass) and diffuse (i.e., global enlargement, poor parenchymal enhancement, lack of excretion of contrast, fat stranding) forms, needs to be differentiated from renal inf…

medicine.medical_specialtyUrinary systemInterstitial nephritisContrast MediaMalignancy030218 nuclear medicine & medical imagingMuscle hypertrophyDiagnosis DifferentialComputed tomography Pyelonephritis Emergency Kidney03 medical and health sciences0302 clinical medicineAtrophyDiabetes mellitusmedicineHumansRadiology Nuclear Medicine and imagingKidneyPyelonephritisbusiness.industry030208 emergency & critical care medicineGold standard (test)medicine.diseasemedicine.anatomical_structureAcute DiseaseChronic DiseaseEmergency MedicineRadiologybusinessTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Früh- und Spätergebnisse der perkutanen transluminalen Angioplastie (PTA) beim Diabetiker

1991

Results of 127 iliac and femoropopliteal transluminal angioplasties in 97 diabetic patients are presented. Patients who had undergone iliac (n = 70), femoral (n = 41), and popliteal (n = 16) angioplasties for stenoses up to 15 cm long were followed up for 6-60 months. In diabetic patients presenting with only claudication or adequate runoff, the 5-year iliac patency rate was 76% and the femoral patency rate was 60%; these results were comparable with those found in non-diabetic patients. For limb salvage, 3-year patency rates were 66% for iliac, 37% for femoral, and 37% for popliteal angioplasties, and 5-year patency rates were 29% for iliac, 7% for femoral, and 0% for popliteal angioplasti…

medicine.medical_specialtyVascular diseasebusiness.industryLimb salvageFemoral arterymedicine.diseasePeripheralSurgeryStenosismedicine.anatomical_structuremedicine.arteryDiabetes mellitusmedicineRadiology Nuclear Medicine and imagingmedicine.symptomClaudicationbusinessArteryRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study

1999

The HAPARG Study (haemostatic parameters as risk factors in healthy volunteers) was performed in a subset of volunteers taking part in the MARISK Study (Mainzer Risikoindikatoren Studie fur die koronare Herzkrankheit) sponsored by the German Ministry of Research and started in 1984. A previous study (Yamanishi et al., Thromb Haemostas 1985;54:539-543) had shown that spontaneously enhanced platelet aggregation as measured with the PAT-III-test and higher fibrinogen concentrations are significant risk factors for new vascular occlusions in diabetic patients. It was the aim of the HAPARG Study to establish whether spontaneous platelet aggregation and other hemostatic variables are independent …

medicine.medical_specialtyVascular diseasebusiness.industryOdds ratiomedicine.diseaseElevated diastolic blood pressureSurgeryBlood pressureInternal medicineDiabetes mellitusmedicineCardiologySpontaneous platelet aggregationRisk factorCardiology and Cardiovascular MedicineProspective cohort studybusinessAtherosclerosis
researchProduct

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

2014

Aims Insulin resistance (IR) is a major risk factor for cardiovascular disease and atherosclerosis. Life-threatening acute events are mainly due to rupture of unstable plaques, and the role of vascular smooth muscle cells (VSMCs) in this process in IR, Type 2 diabetes mellitus, and metabolic syndrome (T2DM/MetS) has not been fully addressed. Therefore, the role of VSMC survival in the generation of unstable plaques in T2DM/MetS and the involvement of inflammatory mediators was investigated. Methods and results Defective insulin receptor substrate 2 (IRS2)-mediated signalling produced insulin-resistant VSMCs with reduced survival, migration, and higher apoptosis than control cells. Silencing…

medicine.medical_specialtyVascular smooth musclePhysiologyCell Survivalmedicine.medical_treatmentMyocytes Smooth MuscleCX3C Chemokine Receptor 1InflammationMice TransgenicBiologyMuscle Smooth VascularInsulin resistanceApolipoproteins EPhysiology (medical)Internal medicinemedicineAnimalsHumansProtein kinase BPI3K/AKT/mTOR pathwayCells CulturedMice KnockoutChemokine CX3CL1Insulinmedicine.diseaseAtherosclerosisIRS2Mice Inbred C57BLAtheromaEndocrinologyDiabetes Mellitus Type 2cardiovascular systemReceptors Chemokinemedicine.symptomInsulin ResistanceCardiology and Cardiovascular MedicineSignal TransductionCardiovascular research
researchProduct

Changes in serum lipid and lipoprotein concentrations and compositions at birth and after 1 month of life in macrosomic infants of insulin-dependent …

1999

The aim of this study was to determine whether macrosomia related to maternal diabetes alters lipoprotein metabolism and whether these abnormalities still persist or regress after 1 month of life. Serum lipoprotein compositions and concentrations as well as serum lipid fatty acid compositions were investigated in macrosomic infants (birth weight = 4840 +/- 105 g at term) of insulin-dependent diabetic mothers at birth and after 1 month of life, and were compared to those of control infants (birth weight = 3400 +/- 198 g at term) of healthy mothers. Compared to controls, at birth, macrosomic newborns had higher serum lipids, apolipoprotein A-I and B-100, and lipoprotein (very low density lipo…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein BBirth weightLipoproteinsPregnancy in DiabeticsBlood lipidsFetal Macrosomiachemistry.chemical_compoundPregnancyReference ValuesInternal medicineDiabetes mellitusmedicineHumanschemistry.chemical_classificationbiologybusiness.industryFatty AcidsInfant NewbornFatty acidmedicine.diseaseLipidsEndocrinologyDiabetes Mellitus Type 1chemistryLow-density lipoproteinCase-Control StudiesPediatrics Perinatology and Child Healthbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessLipoproteinEuropean journal of pediatrics
researchProduct

Statins and diabetes.

2005

Lipid abnormalities play an important part in raising the cardiovascular risk in diabetic subjects. The main components of diabetic dyslipidemia are increased plasma triglycerides, low concentration of high-density lipoprotein cholesterol, preponderance of small, dense low-density lipoprotein, and excessive postprandial lipemia. Small, dense low-density lipoprotein, the elevation in remnant triglyceride-rich lipoprotein particles, and the low high-density lipoprotein are the most powerful atherogenic components. The coexistence of these three factors strongly aggravates the lipid accumulation in the arterial wall and the formation of atherosclerotic plaques. The position of diabetes in card…

medicine.medical_specialtyVery low-density lipoproteinHyperlipidemiasType 2 diabeteschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansTriglyceridebusiness.industrymedicine.diseaseLipidsEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Therapeutic Lifestyle ChangesMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLipoproteinSeminars in vascular medicine
researchProduct

Statins and metabolic syndrome

2003

Abstract Metabolic syndrome (MS) is a multifactorial condition that represents a risk factor for the development of diabetes mellitus (DMII) and cardiovascular disease (CVD). Statins may play a role on some modifiable clinical features of MS; in fact, whereas therapeutic lifestyle changes are mandatory for MS with a 10-year coronary heart disease (CHD) risk 20% and to correct the other associated lipid and non-lipid abnormalities. In fact, they have a VLDL lowering action in hypertriglyceridemia, they reduce the amount of small and dense LDL, they increase the HDL-C, they reduce the atherogenic lipoproteins, and they decrease the inflammatory marker levels.

medicine.medical_specialtyVery low-density lipoproteinbusiness.industryHypertriglyceridemianutritional and metabolic diseasesGeneral MedicineDiseasemedicine.diseaseEndocrinologyDiabetes mellitusInternal medicinemedicineCardiologylipids (amino acids peptides and proteins)RosuvastatinTherapeutic Lifestyle ChangesMetabolic syndromeRisk factorbusinessmedicine.drugInternational Congress Series
researchProduct

Predictive factors of polycystic ovary syndrome in girls with precocious pubarche

2021

Objective: The aim of this study is to clarify, in girls with premature pubarche (PP), the influence of premature androgenization on the prevalence of polycystic ovary syndrome (PCOS). Design and patients: Ninety-nine PP girls, 63 who developed PCOS and 36 who did not develop PCOS, were retrospectively included. Clinical, anthropometric, and metabolic parameters were evaluated at the time of diagnosis of PP and after 10 years from menarche to find predictive factors of PCOS. Results: Young females with PP showed a PCOS prevalence of 64% and showed a higher prevalence of familial history of diabetes (P = 0.004) and a lower prevalence of underweight (P = 0.025) than PP-NO-PCOS. In addition, g…

medicine.medical_specialtyWaistendocrine system diseasesEndocrinology Diabetes and MetabolismDiseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiahyperandrogenismEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusinsulin resistanceInternal MedicinemedicineHyperandrogenism .insulin resistancebusiness.industryResearchHyperandrogenismdyslipidemianutritional and metabolic diseasesvisceral obesitymedicine.diseaseRC648-665Polycystic ovaryEndocrinologyMenarcheUnderweightmedicine.symptomprecocious menarchebusinessDyslipidemiaEndocrine Connections
researchProduct